ClinicalTrials.gg
CompletedNCT05263388ADAPT-1Updated Apr 2, 2025Results posted

A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation

A Phase 3 interventional study of REKOVELLE (Follitropin Delta) and GONAL-F (Follitropin Alfa) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 16 sites in 5 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
5th of 13
302 · median 220
Started
2022
with 1 other
Phase 3
6 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 11th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

Hormone preparations like REKOVELLE and GONAL-F are used to make the body produce multiple egg sacs, allowing more eggs to be collected from women undergoing infertility treatment.

The main purpose of this trial is to see how many eggs are produced with a starting dose of 15 µg REKOVELLE compared to a starting dose of 225 IU GONAL-F. This research is intended to provide more knowledge about REKOVELLE, including the doses given in the trial.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile women aged 18-40 years
  • Diagnosed with tubal infertility, unexplained infertility, mild endometriosis (stage I/II) or partners with decreased sperm quality
  • Medically eligible for in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI)
  • Infertility for at least one year for participants ≤ 37 years or for at least 6 months for participants ≥ 38 years
  • Regular menstrual cycles of 21-35 days.

Exclusion criteria

Exclusion Criteria:

  • Known condition of not functioning ovaries
  • Known advanced endometriosis (stage III/IV)
  • Considered unsuitable for controlled ovarian stimulation with a dosing regimen corresponding to approximately 225 IU/day gonadotropin, as judged by the investigator
  • History of previous episode of OHSS or exuberant ovarian response to gonadotropins, and polycystic ovarian syndrome
  • Any known hormonal or metabolic abnormalities which can compromise participation in the trial
  • Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    REKOVELLE (Follitropin Delta)

    Drug: REKOVELLE (Follitropin Delta)

  • Active comparator
    GONAL-F (Follitropin Alfa)

    Other: GONAL-F (Follitropin Alfa)

Interventions

  • REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.

  • OtherGONAL-F (Follitropin Alfa)

    GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 225 IU fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose could be adjusted by 75 IU based on the participant's response. The minimum GONAL-F dose was 75 IU and the maximum GONAL-F dose was 300 IU. Participants could be treated for a maximum of 20 days.

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    The number of oocytes retrieved was recorded at the oocyte retrieval visit.

    Time frame: On day of oocyte retrieval (Up to 22 days after start of stimulation)

Secondary outcomes

  1. Number of Follicles (Total) at End-of-stimulation

    Counted by transvaginal ultrasound for the right and left ovary for each subject.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  2. Size of the Follicles at End-of-stimulation

    Counted by ultrasound for the right and left ovary for each subject.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  3. Serum Concentrations of Estradiol at End-of-stimulation

    Blood samples for analysis of circulating concentrations of estradiol were drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  4. Serum Concentrations of Progesterone at End-of-stimulation

    Blood samples for analysis of circulating concentrations of progesterone were drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  5. Number of Fertilized Oocytes

    The number of pronuclei were counted after insemination. Fertilized oocytes with 2 pronuclei (2PN) were regarded as correctly fertilized.

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  6. Fertilization Rate

    The fertilization rate was defined as the number of oocytes with 2PN divided by the number of oocytes retrieved.

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  7. Number of Blastocysts and Number of Good Quality Blastocysts

    Number of blastocysts and number of good quality blastocysts on Day 5 or 6 were presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

    Time frame: On Day 5 or Day 6 (as applicable) after oocyte retrieval (up to 27 or 28 days after start of stimulation)

  8. Total Gonadotropin Dose

    Calculated by start dates, end dates and daily dose of investigational medicinal product (IMP).

    Time frame: Up to 20 stimulation days

  9. Number of Stimulation Days

    Calculated by start dates and end dates.

    Time frame: Up to 20 stimulation days

  10. Proportion of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Overall and by Grade) and/or Preventive Interventions for Early OHSS

    Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

    Time frame: Up to 9 days after triggering of final follicular maturation

07

Results

Posted Apr 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Started200100
Completed19694
Not completed46

Outcome measures

PrimaryNumber of Oocytes Retrieved

The number of oocytes retrieved was recorded at the oocyte retrieval visit.

Time frame:
On day of oocyte retrieval (Up to 22 days after start of stimulation)
Reported as:
Median · Oocytes Retrieved
Number of Oocytes Retrieved
Oocytes RetrievedREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Number of Oocytes Retrieved9.0 (6.0 to 13.5)9.0 (6.5 to 13.0)
SecondaryNumber of Follicles (Total) at End-of-stimulation

Counted by transvaginal ultrasound for the right and left ovary for each subject.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Median · Follicles
Number of Follicles (Total) at End-of-stimulation
FolliclesREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Number of Follicles (Total) at End-of-stimulation12.0 (9.0 to 16.0)12.0 (9.0 to 16.0)
SecondarySize of the Follicles at End-of-stimulation

Counted by ultrasound for the right and left ovary for each subject.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Median · mm
Size of the Follicles at End-of-stimulation
mmREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Size of the Follicles at End-of-stimulation15.7 (14.7 to 16.8)16.0 (15.1 to 16.9)
SecondarySerum Concentrations of Estradiol at End-of-stimulation

Blood samples for analysis of circulating concentrations of estradiol were drawn.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Median · pmol/L
Serum Concentrations of Estradiol at End-of-stimulation
pmol/LREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Serum Concentrations of Estradiol at End-of-stimulation6085.0 (3516.0 to 8602.0)5853.5 (4053.5 to 9742.0)
SecondarySerum Concentrations of Progesterone at End-of-stimulation

Blood samples for analysis of circulating concentrations of progesterone were drawn.

Time frame:
At end-of-stimulation (up to 20 stimulation days)
Reported as:
Median · nmol/L
Serum Concentrations of Progesterone at End-of-stimulation
nmol/LREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Serum Concentrations of Progesterone at End-of-stimulation2.9 (1.9 to 3.8)2.5 (1.6 to 3.5)
SecondaryNumber of Fertilized Oocytes

The number of pronuclei were counted after insemination. Fertilized oocytes with 2 pronuclei (2PN) were regarded as correctly fertilized.

Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Median · Oocytes
Number of Fertilized Oocytes
OocytesREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Number of Fertilized Oocytes5.0 (3.0 to 8.0)5.0 (3.0 to 7.0)
SecondaryFertilization Rate

The fertilization rate was defined as the number of oocytes with 2PN divided by the number of oocytes retrieved.

Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Median · percentage of oocytes fertilised
Fertilization Rate
percentage of oocytes fertilisedREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Fertilization Rate54.5 (40.0 to 71.4)57.7 (40.0 to 71.4)
SecondaryNumber of Blastocysts and Number of Good Quality Blastocysts

Number of blastocysts and number of good quality blastocysts on Day 5 or 6 were presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

Time frame:
On Day 5 or Day 6 (as applicable) after oocyte retrieval (up to 27 or 28 days after start of stimulation)
Reported as:
Median · Blastocysts
Number of Blastocysts and Number of Good Quality Blastocysts
BlastocystsREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Number of Blastocysts2.0 (1.0 to 5.0)3.0 (1.0 to 4.5)
Number of good quality blastocysts2.0 (1.0 to 4.0)2.0 (0.0 to 3.0)
SecondaryTotal Gonadotropin Dose

Calculated by start dates, end dates and daily dose of investigational medicinal product (IMP).

Time frame:
Up to 20 stimulation days
Reported as:
Median · ug
Total Gonadotropin Dose
ugREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Total Gonadotropin Dose135 (120.0 to 160.0)148.5 (137.5 to 165.0)
SecondaryNumber of Stimulation Days

Calculated by start dates and end dates.

Time frame:
Up to 20 stimulation days
Reported as:
Median · days
Number of Stimulation Days
daysREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Number of Stimulation Days9.0 (8.0 to 10.0)9.0 (8.0 to 10.0)
SecondaryProportion of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Overall and by Grade) and/or Preventive Interventions for Early OHSS

Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.

Time frame:
Up to 9 days after triggering of final follicular maturation
Reported as:
Count of participants · Participants
Proportion of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Overall and by Grade) and/or Preventive Interventions for Early OHSS
ParticipantsREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
Early OHSS (any grade)53
Early OHSS (moderate/severe)11
Early OHSS (any grade) and / or preventative interventions3317
Early OHSS (moderate/severe) and / or preventative interventions3016

Adverse events

Collected over 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REKOVELLE (Follitropin Delta)0/200 (0%)0/200 (0%)24/200 (12%)
GONAL-F (Follitropin Alfa)0/100 (0%)2/100 (2%)11/100 (11%)
Most frequent serious events
Most frequent serious events
EventREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
HaemoperitoneumGastrointestinal disorders0/2002/100
Most frequent other events
Most frequent other events
EventREKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)
HeadacheNervous system disorders23/2008/100
Pelvic painReproductive system and breast disorders1/2005/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
Mean34.5 ± 3.834.5 ± 3.434.5 ± 3.7
Age, Customized
Age, Customized(Participants)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
<35 Years8343126
35 - 37 Years7439113
38 - 40 Years431861
Sex: Female, Male
Sex: Female, Male(Participants)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
Female200100300
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
Hispanic or Latino272047
Not Hispanic or Latino17380253
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
American Indian or Alaska Native112
Asian707
Native Hawaiian or Other Pacific Islander000
Black or African American112
White19198289
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)REKOVELLE (Follitropin Delta)GONAL-F (Follitropin Alfa)Total
Austria462268
Italy351550
United Kingdom291342
France538
Spain8547132
08

Study locations

16 sites
  • Ferring Investigational Site
    Wals-Seizenheim, Salzburg, Austria
  • Ferring Investigational Site
    Wien, Austria
  • Ferring Investigational Site
    Montpellier, France
  • Ferring Investigational Site
    Paris, France
  • Ferring Investigational Site
    Firenze, Italy
  • Ferring Investigational Site
    Milano, Italy
  • Ferring Investigational Site
    Napoli, Italy
  • Ferring Investigational Site
    Roma, Italy
  • Ferring Investigational Site
    Alicante, Spain
  • Ferring Investigational Site
    Barcelona, Spain
  • Ferring Investigational Site
    Bilbao, Spain
  • Ferring Investigational Site
    Madrid, Spain
  • Ferring Investigational Site
    Malaga, Spain
  • Ferring Investigational Site
    Valladolid, Spain
  • Ferring Investigational Site
    Coventry, United Kingdom
  • Ferring Investigational Site
    Liverpool, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2024, 21 months.

Results were first posted in Apr 2025, 11 months after primary completion.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Mar 2, 2022
StartActual
Jul 15, 2022
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Results first posted
Apr 2, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05263388
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Jul 15, 2022
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Results posted
Apr 2, 2025
Last update
Apr 2, 2025

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion